➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Medtronic
Moodys
Baxter
Merck

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,084,765


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,084,765 protect, and when does it expire?

Patent 9,084,765 protects BARHEMSYS and is included in one NDA.

This patent has fifty patent family members in twenty-five countries.

Summary for Patent: 9,084,765
Title:Use of amisulpride as an anti-emetic
Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Inventor(s): Gilbert; Julian Clive (Cambridgeshire, GB), Gristwood; Robert William (Cambridge, GB), Cooper; Nicola (Essex, GB), Fox; Gabriel (Cambridgeshire, GB)
Assignee: Acacia Pharma Limited (Cambridgeshire, GB)
Application Number:13/559,168
Patent Claim Types:
see list of patent claims
Use; Delivery;

Recent additions to Drugs Protected by US Patent 9,084,765

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Acacia Pharma Ltd BARHEMSYS amisulpride SOLUTION 209510 Feb 26, 2020 RX Yes   Start Trial   Start Trial U-1744 PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Acacia Pharma Ltd BARHEMSYS amisulpride SOLUTION 209510 Feb 26, 2020 RX Yes   Start Trial   Start Trial U-2754 TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 9,084,765

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acacia Pharma Ltd BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-001 Feb 26, 2020 RX Yes Yes   Start Trial   Start Trial PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING   Start Trial
Acacia Pharma Ltd BARHEMSYS amisulpride SOLUTION;INTRAVENOUS 209510-001 Feb 26, 2020 RX Yes Yes   Start Trial   Start Trial TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,084,765

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom1004020.2Mar 11, 2010

International Family Members for US Patent 9,084,765

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011225898   Start Trial
Brazil 112012022746   Start Trial
Canada 2792392   Start Trial
China 102892407   Start Trial
Cyprus 1115485   Start Trial
Cyprus 1115487   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
McKinsey
Express Scripts
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.